Effect of Ranibizumab on Malignant Conjunctival Neoplasia.

Trial Profile

Effect of Ranibizumab on Malignant Conjunctival Neoplasia.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Eye neoplasms
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Dec 2008 Planned number of patients changed from 20 to 10 as reported by ClinicalTrials.gov.
    • 30 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top